Arbutus Biopharma Corp (ABUS) Total liabilities 2016–2025
Arbutus Biopharma Corp (ABUS) total liabilities at each fiscal year-end, per SEC filings.
$18.0MFY2025 · since FY2016: $72.9M → $18.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $18.0M | -47.5% |
| FY2024 | $34.3M | -10.5% |
| FY2023 | $38.4M | -34.5% |
| FY2022 | $58.6M | +67.1% |
| FY2021 | $35.0M | -0.2% |
| FY2020 | $35.1M | +7.1% |
| FY2019 | $32.8M | +18.5% |
| FY2018 | $27.7M | -49.4% |
| FY2017 | $54.7M | -25.0% |
| FY2016 | $72.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Net marginABUS Gross profitABUS Gross marginABUS Operating incomeABUS Operating marginABUS Operating cash flowABUS Free cash flowABUS Capital expendituresABUS Return on equityABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Shareholders’ equityABUS overview →